United Laboratories Unit's Chronic Kidney Disease Drug Gets US Clinical Trial Approval
MT Newswires Live03-04
United Laboratories International Holdings (HKG:3933) said its subsidiary's UBT251 drug received approval from the US Food and Drug Administration for a Phase II clinical trial targeting chronic kidney disease (CKD), according to a Monday filing with the Hong Kong Exchange.
Based on the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251
demonstrated "significantly superior overall improvement effects on renal urinary albumin and
other related renal injury markers and histopathology than Semaglutide," United Laboratories said.
UBT251, developed by United Laboratories subsidiary The United Bio-Technology (Hengqin), received clinical trial authorization in China in January for the same indication.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
